Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

Kruis, W.; Frič, P.; Pokrotnieks, J.; Lukáš, M.; Fixa, B.; Kasščák, M.; Kamm, M. A.; Weismueller, J.; Beglinger, C.; Stolte, M.; Wolff, C.
November 2004
Gut;Nov2004, Vol. 53 Issue 11, p1617
Academic Journal
Background and aim: Evidence exists for the pathogenic role of the enteric flora in inflammatory bowel disease. Probiotics contain living microorganisms which exert health effects on the host. We compared the efficacy in maintaining remission of the probiotic preparation Escherichia coli Nissle 1917 and established therapy with mesalazine in patients with ulcerative colitis. Patients and methods: In total, 327 patients were recruited and assigned to a double blind, double dummy trial to receive either the probiotic drug 200 mg once daily (n = 162) or mesalazine 500 mg three times daily (n = 165). The study lasted for 12 months and patients were assessed by clinical and endoscopic activity indices (Rachmilewitz) as well as by histology. The primary aim of the study was to confirm equivalent efficacy of the two drugs in the prevention of relapses. Results: The per protocol analysis revealed relapses in 40/110 (36.4%) patients in the E coli Nissle 1917 group and 38/112 (33.9%) in the mesalazine group (significant equivalence p = 0.003). Subgroup analyses showed no differences between the treatment groups in terms of duration and localisation of disease or pretrial treatment. Safety profile and tolerability were very good for both groups and were not different. Conclusions: The probiotic drug E coli Nissle 1917 shows efficacy and safety in maintaining remission equivalent to the gold standard mesalazine in patients with ulcerative colitis. The effectiveness of probiotic treatment further underlines the pathogenetic significance of the enteric flora.


Related Articles

  • Increased gut permeability in Crohn's disease: is TNF the link?  // Gut;Dec2004, Vol. 53 Issue 12, p1724 

    No abstract available.

  • Probiotic is useful for ulcerative colitis. Kruis, W.; Fric, P.; Pokrotnieks, J. // BMJ: British Medical Journal (International Edition);5/7/2005, Vol. 330 Issue 7499, Preceding p1035 

    Looks at the use of the probiotic Escherichia coli Nissle 1917 (EcN) in the treatment of ulcerative colitis. View that EcN is a Gram negative probiotic and may work by causing an immune response or preventing invasion of other bacteria; Review of study investigating the effect of EcN on...

  • "Germ Warfare" for Ulcerative Colitis? Bahrani, Otarod; Flemmer, Mark // American Journal of Gastroenterology;Apr2001, Vol. 96 Issue 4, p1293 

    A single center randomized double dummy study was undertaken in 116 patients; 59 were randomized to mesalamine and 57 to receive a nonpathogenic strain of Escherichia coli. In addition, all patients received standard medical therapy, together with a 1-wk course of oral gentamicin. After...

  • The Hair of the Dog. Bahrani, Otarod; Flemmer, Mark; Johnson, David // American Journal of Gastroenterology;Sep2001, Vol. 96 Issue 9, p2789 

    A single-center randomized double dummy study was undertaken in 116 patients; 59 were randomized to mesalamine and 57 to receive a nonpathogenic strain of Escherichia coli. In addition, all patients received standard medical therapy, together with a 1-wk course of oral gentamicin. After...

  • Escherichia coli and ulcerative colitis. Burke, Denis // Journal of the Royal Society of Medicine;Nov1997, Vol. 90 Issue 11, p612 

    The article provides information about ulcerative colitis and escherichia coli. The clinical characteristics of acute ulcerative colitis in relapse are quite similar to that of infectious colitis. Conflicting results have been produced by the quantitative studies of the faecal flora in...

  • Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). Matthes, Harald; Krummenerl, Thomas; Giensch, Manfred; Wolff, Corinna; Schulze, Jürgen // BMC Complementary & Alternative Medicine;2010, Vol. 10, p13 

    Background: Probiotics are effective in inflammatory bowel diseases. Clinical effectiveness and dose dependency of E. coli Nissle (EcN) enemas were investigated in ulcerative colitis (UC). Methods: In a double-blind study, 90 patients with moderate distal activity in UC were randomly assigned to...

  • LACTOBACILLUS PREVENTS RELAPSE IN ULCERATIVE COLITIS.  // Pulse;8/10/2006, Vol. 66 Issue 31, p25 

    The article focuses on the prevention of relapse in patients with ulcerative colitis through regular treatment with Lactobacillus rhamnosus GG. LGG has been used successfully to treat travellers' diarrhea and antibiotic-associated diarrhea. The evidence for the effectiveness of Lactobacillus...

  • Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Thomas, Saskia; Baumgart, Daniel // Inflammopharmacology;Feb2012, Vol. 20 Issue 1, p1 

    Crohn's disease and ulcerative colitis are two chronic inflammatory bowel diseases. Current biologic therapies are limited to blocking tumor necrosis factor alpha. However, some patients are primary non-responders, experience a loss of response, intolerance or side effects defining the urgent...

  • Probiotics, prebiotics, synbiotics: ecological treatment for inflammatory bowel disease? Marteau, P. // Gut;Dec2006, Vol. 55 Issue 12, p1692 

    The author reflects on the ecological treatment for inflammatory bowel disease of probiotics, prebiotics, and synbiotics. An overview of the several studies conducted on probiotics, prebiotics, and synbiotics are offered. He views that these researches will offer a large field of potential...


Read the Article


Sign out of this library

Other Topics